Law firm Pomerantz LLP is investigating Organon & Co. (OGN) for potential securities fraud or other unlawful business practices after the pharmaceutical company's Q4 2023 financial results showed a decline in earnings per share and revenue, as well as a revenue reduction for the quarter, causing the stock to fall by 15% to $24.87 per share.
Organon & Co. (OGN) stock went down by 2.54% following an investigation by Pomerantz LLP into possible securities fraud or other unlawful business practices by the company and its officers and/or directors, after Organon's earnings per share and revenue declined year-over-year, and due to the market action taken in certain markets for betamethasone suspension injections.
Organon & Co.'s stock (OGN) went down by 1.58% due to the announcement of a new global initiative, "Her Plan is Her Power," aimed at reducing unplanned pregnancies and empower women and girls when it comes to their sexual and reproductive health. The company has committed to $30 million in new funding for the program from 2023 to 2025 to address inequities and accelerate progress in resolving the global public health crisis of unplanned pregnancy.
The release of Organon's financial results, which were not positive, caused the stock price to drop.
Organon & Co. (OGN) stock falls following disappointing financial results.
Organon & Co. (OGN) provides pharmaceutical products and health information technology services.
Organon & co.(OGN) is a pharmaceutical company that develops and manufactures medications for the treatment of various diseases.
Organon & Co. (OGN) stock goes down in one sentence because the company has reported weaker then expected financial results for the fourth quarter and full year 2022.
Organon & Co. is scheduled to release its financial results on Feb. 16, 2023. The company's stock went down following the announcement.
Organon & Co. (OGN) shares lower today after announcing a strategic investment in Claria Medical, Inc. which will allow the company to explore safer and simpler ways to provide medical procedures to women.
the company said it plans to acquire Forendo Pharma